← All trials
NCT03088111
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2025
- First posted
- Mar 23, 2017
- Last posted
- Jul 14, 2023
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Elusys TherapeuticsLead sponsor
- APCER Life SciencesCollaborator
- Centers for Disease Control and Prevention (CDC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.